The breast

ISSNs: 0960-9776

Additional searchable ISSN (electronic): 1532-3080

Churchill Livingstone

Scopus rating (2022): CiteScore 6.7 SJR 1.269 SNIP 1.329

Indexed in DOAJ

Journal

Titles	The breast(1992 → 2019) Breast
Additional searchable titles	Breast (Edinburgh, Scotland), The Breast, Breast
ISSNs	0960-9776
Additional searchable ISSN (electronic)	1532-3080
Publisher	Churchill Livingstone
ZDB-ID	1143210-X
ZDB-ID	2009043-2

Keywords

ASJC Scopus subject areas

Library keywords

610 Medicine and health

Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011))

Schneeweiss, A., Ettl, J., Lüftner, D., Beckmann, M. W., Belleville, E., Fasching, P. A., Fehm, T. N., & 27 othersGeberth, M., Häberle, L., Hadji, P., Hartkopf, A. D., Hielscher, C., Huober, J., Ruckhäberle, E., Janni, W., Kolberg, H. C., Kurbacher, C. M., Klein, E., Lux, M. P., Müller, V., Nabieva, N., Overkamp, F., Tesch, H., Laakmann, E., Taran, F. A., Seitz, J., Thomssen, C., Untch, M., Wimberger, P., Wuerstlein, R., Volz, B., Wallwiener, D., Wallwiener, M. & Brucker, S. Y., Feb 2021, Breast, 55, p. 138-139 2 p.

Research output: Contribution to specialist publication › Corrections (errata and retractions) › peer-review

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Research output: Contribution to journal › Research article › Contributed › peer-review

Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women

Weiner, C. M., Mathewos, A., Addissie, A., Ayele, W., Aynalem, A., Wondemagegnehu, T., Wienke, A., & 5 othersJemal, A., Zerche, P., Thomssen, C., Seidler, A. & Kantelhardt, E. J., Dec 2018, In: The breast. 42, p. 23-30 8 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial

Schwentner, L., Harbeck, N., Singer, S., Eichler, M., Rack, B., Forstbauer, H., Wischnik, A., & 8 othersScholz, C., Huober, J., Friedl, T. W. P., Weissenbacher, T., Härtl, K., Kiechle, M., Janni, W. & Fink, V., 1 Jun 2016, In: The breast. 27, p. 69-77 9 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Aesthetic and functional correction of female, asymmetric funnel chest - a combined approach.

Dragu, A., 3 Feb 2009, In: The breast.

Research output: Contribution to journal › Research article › Contributed › peer-review

View all research output (5)

Research Portal of the TU Dresden

The breast

Keywords

ASJC Scopus subject areas

Library keywords

Related content

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial

Aesthetic and functional correction of female, asymmetric funnel chest - a combined approach.